656805-52-6Relevant academic research and scientific papers
Benzodioxoles: Novel cannabinoid-1 receptor inverse agonists for the treatment of obesity
Alig, Leo,Alsenz, Jochem,Andjelkovic, Mirjana,Bendels, Stefanie,Bénardeau, Agnès,Bleicher, Konrad,Bourson, Anne,David-Pierson, Pascale,Guba, Wolfgang,Hildbrand, Stefan,Kube, Dagmar,Lübbers, Thomas,Mayweg, Alexander V.,Narquizian, Robert,Neidhart, Werner,Nettekoven, Matthias,Plancher, Jean-Marc,Rocha, Cynthia,Rogers-Evans, Mark,R?ver, Stephan,Schneider, Gisbert,Taylor, Sven,Waldmeier, Pius
, p. 2115 - 2127 (2008/12/22)
The application of the evolutionary fragment-based de novo design tool TOPology Assigning System (TOPAS), starting from a known CB1R (CB-1 receptor) ligand, followed by further refinement principles, including pharmacophore compliance, chemical tractabili
Heterocyclic CB1 receptor antagonists
-
Page/Page column 8, (2010/11/08)
The present invention relates to compounds of formula wherein R1 and R2 are each independently hydrogen or halogen. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of
Spiro-pentacyclic compounds
-
Page/Page column 9, (2010/02/13)
The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts thereof, for use as therapeutically active substances. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with
NOVEL BENZODIOXOLES
-
Page 144, (2008/06/13)
The present invention relates to compound of formula (I) Wherein R1, R2, R3, R4, R5, R6, R7, and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases, which are associated with the modulation of CB1 receptors.
